InsidersTradesSigma
Total declarations
Companies
▲ Purchases (16 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
16
Disclosed sells
0
T+90 hit rate
9%
T+90 mean return
-43.1%
Across 11 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by PATIENCE JOHN, Director. Director active across 2 companies, notably BIODESIX INC. Aggregated, 22 filings have been published. Split: 16 buys · 0 sell. Total volume traded: €4.2m. Activity tracked since 17 August 2021. The latest transaction was filed on 3 December 2024 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations22 total
1,361 sharesCommon StockSEC:0000905148-26-003146:0
46,686 sharesCommon StockSEC:0000905148-25-001047:0
200,000 shares@ US$1.5750.9% of flowCommon StockSEC:0001104659-24-125217:0
Ideal exit: 30 Aug 2025 (T+270)
75,000 shares@ US$1.38282.4% of flowCommon StockSEC:0000905148-24-002948:0
Ideal exit: 2 Aug 2025 (T+270)
217,400 sharesCommon StockSEC:0000905148-24-001605:0
16,666 sharesCommon StockSEC:0001104659-24-006670:0
Ideal exit: 19 Oct 2024 (T+270)
61,728 shares@ US$1.622.3% of flowCommon StockSEC:0000905148-23-000626:0
1,739,130 shares@ US$1.1548.5% of flowCommon StockSEC:0001140361-22-042602:0
Ideal exit: 18 Aug 2023 (T+270)
279,329 shares@ US$1.790.85% mcap24.6% of flowCommon StockSEC:0001567619-22-008354:0
Ideal exit: 2 Jan 2023 (T+270)
137,931 shares@ US$4.3513.2% of flowCommon StockSEC:0001567619-22-000275
Ideal exit: 26 Sept 2022 (T+270)
137,931 shares@ US$4.350.98% mcap28.3% of flowCommon StockSEC:0001567619-22-000275:0
Ideal exit: 26 Sept 2022 (T+270)
21,702 shares@ US$7.6824.5% of flowCommon StockSEC:0001628280-21-024838
21,702 shares@ US$7.6850.0% of flowCommon StockSEC:0001628280-21-024838:0
10,000 shares@ US$6.17530.10% mcap2.9% of flowCommon StockSEC:0001567619-21-021148:0
Ideal exit: 20 Aug 2022 (T+270)
10,000 shares@ US$6.17531.4% of flowCommon StockSEC:0001567619-21-021148
Ideal exit: 20 Aug 2022 (T+270)
9,497 shares@ US$6.34091.3% of flowCommon StockSEC:0001567619-21-020954
Ideal exit: 15 Aug 2022 (T+270)
9,497 shares@ US$6.34090.098% mcap2.8% of flowCommon StockSEC:0001567619-21-020954:0
Ideal exit: 15 Aug 2022 (T+270)
8,396 shares@ US$8.03830.11% mcap3.1% of flowCommon StockSEC:0001567619-21-016211:0
Ideal exit: 16 May 2022 (T+270)
8,396 shares@ US$8.03831.4% of flowCommon StockSEC:0001567619-21-016211
Ideal exit: 16 May 2022 (T+270)
1,604 shares@ US$7.11740.018% mcap0.5% of flowCommon StockSEC:0000905148-21-000612:0
Ideal exit: 14 May 2022 (T+270)
1,604 shares@ US$7.11740.2% of flowCommon StockSEC:0000905148-21-000612
Ideal exit: 14 May 2022 (T+270)
50,000 sharesCommon StockSEC:0001144204-16-080134:0
Ideal exit: 5 Nov 2016 (T+270)
22 of 22 declarations
About PATIENCE JOHN
PATIENCE JOHN is a Director at BIODESIX INC and Accelerate Diagnostics, Inc. In this role, he contributes to overseeing the activities of these companies and making strategic decisions. His expertise is valuable for guiding these organizations in their development initiatives.
